Early signs CAR NKs could compete with CAR Ts in heme cancers
CAR NK cells could give CAR Ts a run for their money if early efficacy signals hold up
Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing and fewer safety risks.
Though the data come from only 11 patients, a study from University of Texas MD Anderson Cancer Center has found an efficacy signal for a CD19-targeted CAR NK cell therapy that is in line with marketed CAR T cells against the same target.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;